12 results on '"Renda, Teresa"'
Search Results
2. Assessment of asthma control: The SERENA study
- Author
-
Corrado, Antonio, Renda, Teresa, Polese, Guido, and Rossi, Andrea
- Published
- 2013
- Full Text
- View/download PDF
3. ERS clinical practice guidelines: high-flow nasal cannula in acute respiratory failure
- Author
-
Oczkowski, Simon, primary, Ergan, Begüm, additional, Bos, Lieuwe, additional, Chatwin, Michelle, additional, Ferrer, Miguel, additional, Gregoretti, Cesare, additional, Heunks, Leo, additional, Frat, Jean-Pierre, additional, Longhini, Federico, additional, Nava, Stefano, additional, Navalesi, Paolo, additional, Ozsancak Uğurlu, Aylin, additional, Pisani, Lara, additional, Renda, Teresa, additional, Thille, Arnaud W., additional, Winck, João Carlos, additional, Windisch, Wolfram, additional, Tonia, Thomy, additional, Boyd, Jeanette, additional, Sotgiu, Giovanni, additional, and Scala, Raffaele, additional
- Published
- 2021
- Full Text
- View/download PDF
4. Is early detection of late-onset Pompe disease a pneumologist's affair? A lesson from an Italian screening study 11 Medical and Health Sciences 1103 Clinical Sciences
- Author
-
Confalonieri, Marco, Vitacca, Michele, Scala, Raffaele, Polverino, Mario, Sabato, Eugenio, Crescimanno, Grazia, Ceriana, Piero, Antonaglia, Caterina, Siciliano, Gabriele, Ring, Nadja, Zacchigna, Serena, Salton, Francesco, Vianello, Andrea, Mattei, Alessio, De Michele, Fausto, Triolo, Luca, Culla, Giuseppe, Canessa, Pieraldo, Girbino, Giuseppe, Lusuardi, Mirco, Perretta, Enrico, De Michelis, Claudio, and Renda, Teresa
- Subjects
Respiratory high dependency care unit ,Acute respiratory failure ,Diagnosis ,Late-onset Pompe disease ,Noninvasive ventilation ,Genetics (clinical) ,Pharmacology (medical) - Published
- 2019
5. Update on optimal use of omalizumab in management of asthma
- Author
-
Pelaia,Girolamo, Gallelli,Luca, Renda,Teresa, Romeo,Pasquale, Busceti,Maria Teresa, Grembiale,Rosa Daniela, Maselli,Rosario, Marsico,Serafino Antonio, Vatrella,Alessandro, Pelaia,Girolamo, Gallelli,Luca, Renda,Teresa, Romeo,Pasquale, Busceti,Maria Teresa, Grembiale,Rosa Daniela, Maselli,Rosario, Marsico,Serafino Antonio, and Vatrella,Alessandro
- Abstract
Girolamo Pelaia1, Luca Gallelli1, Teresa Renda1, Pasquale Romeo1, Maria Teresa Busceti1, Rosa Daniela Grembiale1, Rosario Maselli1, Serafino Antonio Marsico2, Alessandro Vatrella31Department of Experimental and Clinical Medicine, University Magna Græcia of Catanzaro, Catanzaro; 2Department of Cardiothoracic and Respiratory Sciences, Second University of Naples, Naples; 3Department of Respiratory Medicine, University of Salerno, Salerno, ItalyAbstract: Omalizumab is a humanized monoclonal anti-IgE antibody recently approved for the treatment of severe allergic asthma. This drug inhibits allergic responses by binding to serum IgE, thus preventing interaction with cellular IgE receptors. Omalizumab is also capable of downregulating the expression of high affinity IgE receptors on inflammatory cells, as well as the numbers of eosinophils in both blood and induced sputum. The clinical effects of omalizumab include improvements in respiratory symptoms and quality of life, paralleled by a reduction of asthma exacerbations, emergency room visits, and use of systemic corticosteroids and rescue bronchodilators. Omalizumab is relatively well-tolerated, and only rarely induces anaphylactic reactions. Therefore, this drug represents a valid option as add-on therapy for patients with severe persistent allergic asthma inadequately controlled by high doses of standard inhaled treatments.Keywords: omalizumab, anti-IgE, severe asthma
- Published
- 2011
6. Molecular mechanisms underlying airway smooth muscle contraction and proliferation: Implications for asthma
- Author
-
Pelaia, Girolamo, primary, Renda, Teresa, additional, Gallelli, Luca, additional, Vatrella, Alessandro, additional, Busceti, Maria Teresa, additional, Agati, Sergio, additional, Caputi, Mario, additional, Cazzola, Mario, additional, Maselli, Rosario, additional, and Marsico, Serafino A., additional
- Published
- 2008
- Full Text
- View/download PDF
7. Biological targets for therapeutic interventions in COPD: clinical potential
- Author
-
Pelaia, Girolamo, primary, Vatrella, Alessandro, additional, Gallelli, Luca, additional, Renda, Teresa, additional, Caputi, Mario, additional, Maselli, Rosario, additional, and Marsico, Serafino A, additional
- Published
- 2006
- Full Text
- View/download PDF
8. Respiratory infections and asthma
- Author
-
Pelaia, Girolamo, primary, Vatrella, Alessandro, additional, Gallelli, Luca, additional, Renda, Teresa, additional, Cazzola, Mario, additional, Maselli, Rosario, additional, and Marsico, Serafino A., additional
- Published
- 2006
- Full Text
- View/download PDF
9. Update on optimal use of omalizumab in management of asthma.
- Author
-
Pelaia, Girolamo, Gallelli, Luca, Renda, Teresa, Romeo, Pasquale, Teresa Busceti, Maria, Daniela Grembiale, Rosa, Maselli, Rosario, Antonio Marsico, Serafino, and Vatrella, Alessandro
- Published
- 2011
- Full Text
- View/download PDF
10. High-Flow Nasal Cannula and COVID-19: A Clinical Review
- Author
-
Claudia Crimi, Lara Pisani, Paola Pierucci, Teresa Renda, Annalisa Carlucci, Crimi, Claudia, Pierucci, Paola, Renda, Teresa, Pisani, Lara, and Carlucci, Annalisa
- Subjects
Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,ARDS ,Coronavirus disease 2019 (COVID-19) ,medicine.medical_treatment ,Critical Care and Intensive Care Medicine ,medicine.disease_cause ,Oxygen therapy ,Pandemic ,Cannula ,Humans ,Medicine ,Continuous positive airway pressure ,Intensive care medicine ,Acute hypoxemic respiratory failure ,Noninvasive Ventilation ,SARS-CoV-2 ,business.industry ,Oxygen Inhalation Therapy ,COVID-19 ,General Medicine ,medicine.disease ,Pneumonia ,Tolerability ,High-flow nasal cannula ,Narrative Review ,Respiratory Insufficiency ,business ,Nasal cannula ,Human - Abstract
During the coronavirus disease 2019 (COVID-19) pandemic, noninvasive respiratory support has played a central role in managing patients affected by moderate-to-severe acute hypoxemic respiratory failure, despite inadequate scientific evidence to support its usage. High-flow nasal cannula (HFNC) treatment has gained tremendous popularity because of its effectiveness in delivering a high fraction of humidified oxygen, which improves ventilatory efficiency and the respiratory pattern, as well as its reported high tolerability, ease of use, and application outside of ICUs. Nevertheless, the risk of infection transmission to health-care workers has raised some concerns about its use in the first wave of the pandemic outbreak, with controversial recommendations provided by different scientific societies. This narrative review provides an overview of the recent evidence on the physiologic rationale, risks, and benefits of using HFNC instead of conventional oxygen therapy and other types of noninvasive respiratory support devices, such as continuous positive airway pressure and noninvasive ventilation in patients affected by COVID-19 pneumonia with associated acute hypoxemic respiratory failure. It also summarizes the available evidence with regard to the clinical use of HFNC during the current pandemic and its reported outcomes, and highlights the risks of bioaerosol dispersion associated with HFNC use.
- Published
- 2021
11. ERS clinical practice guidelines:high-flow nasal cannula in acute respiratory failure
- Author
-
Giovanni Sotgiu, Miguel Ferrer, Cesare Gregoretti, Jean-Pierre Frat, Aylin Ozsancak Ugurlu, Begüm Ergan, Leo M. A. Heunks, Jeanette Boyd, Raffaele Scala, Lieuwe D. J. Bos, Teresa Renda, Michelle Chatwin, Federico Longhini, Simon Oczkowski, Lara Pisani, Stefano Nava, Wolfram Windisch, João Carlos Winck, Thomy Tonia, Arnaud W. Thille, Paolo Navalesi, Oczkowski, Simon, Ergan, Begüm, Bos, Lieuwe, Chatwin, Michelle, Ferrer, Miguel, Gregoretti, Cesare, Heunks, Leo, Frat, Jean-Pierre, Longhini, Federico, Nava, Stefano, Navalesi, Paolo, Uğurlu, Aylin Ozsancak, Pisani, Lara, Renda, Teresa, Thille, Arnaud W, Winck, João Carlo, Windisch, Wolfram, Tonia, Thomy, Boyd, Jeanette, Sotgiu, Giovanni, Scala, Raffaele, Pulmonary medicine, ACS - Heart failure & arrhythmias, Intensive Care Medicine, AII - Inflammatory diseases, and Ozsancak Uğurlu, Aylin
- Subjects
Pulmonary and Respiratory Medicine ,Adult ,medicine.medical_specialty ,medicine.medical_treatment ,medicine.disease_cause ,Internal medicine ,Oxygen therapy ,medicine ,Cannula ,Humans ,Acute respiratory failure ,Intensive care medicine ,COPD ,Respiratory Distress Syndrome ,Noninvasive Ventilation ,business.industry ,Oxygen Inhalation Therapy ,chronic respiratory failure - COPD - noinvasive ventilation ,medicine.disease ,Clinical Practice ,Oxygen ,Pulmonology ,Breathing ,High flow ,business ,Respiratory Insufficiency ,Nasal cannula - Abstract
BackgroundHigh-flow nasal cannula (HFNC) has become a frequently used noninvasive form of respiratory support in acute settings; however, evidence supporting its use has only recently emerged. These guidelines provide evidence-based recommendations for the use of HFNC alongside other noninvasive forms of respiratory support in adults with acute respiratory failure (ARF).Materials and methodologyThe European Respiratory Society task force panel included expert clinicians and methodologists in pulmonology and intensive care medicine. The task force used the GRADE (Grading of Recommendations, Assessment, Development and Evaluation) methods to summarise evidence and develop clinical recommendations for the use of HFNC alongside conventional oxygen therapy (COT) and noninvasive ventilation (NIV) for the management of adults in acute settings with ARF.ResultsThe task force developed eight conditional recommendations, suggesting the use of 1) HFNC over COT in hypoxaemic ARF; 2) HFNC over NIV in hypoxaemic ARF; 3) HFNC over COT during breaks from NIV; 4) either HFNC or COT in post-operative patients at low risk of pulmonary complications; 5) either HFNC or NIV in post-operative patients at high risk of pulmonary complications; 6) HFNC over COT in nonsurgical patients at low risk of extubation failure; 7) NIV over HFNC for patients at high risk of extubation failure unless there are relative or absolute contraindications to NIV; and 8) trialling NIV prior to use of HFNC in patients with COPD and hypercapnic ARF.ConclusionsHFNC is a valuable intervention in adults with ARF. These conditional recommendations can assist clinicians in choosing the most appropriate form of noninvasive respiratory support to provide to patients in different acute settings.
- Published
- 2022
12. ERS clinical practice guidelines: high-flow nasal cannula in acute respiratory failure.
- Author
-
Oczkowski S, Ergan B, Bos L, Chatwin M, Ferrer M, Gregoretti C, Heunks L, Frat JP, Longhini F, Nava S, Navalesi P, Ozsancak Uğurlu A, Pisani L, Renda T, Thille AW, Winck JC, Windisch W, Tonia T, Boyd J, Sotgiu G, and Scala R
- Subjects
- Adult, Cannula, Humans, Oxygen, Oxygen Inhalation Therapy methods, Noninvasive Ventilation methods, Respiratory Distress Syndrome therapy, Respiratory Insufficiency etiology, Respiratory Insufficiency therapy
- Abstract
Background: High-flow nasal cannula (HFNC) has become a frequently used noninvasive form of respiratory support in acute settings; however, evidence supporting its use has only recently emerged. These guidelines provide evidence-based recommendations for the use of HFNC alongside other noninvasive forms of respiratory support in adults with acute respiratory failure (ARF)., Materials and Methodology: The European Respiratory Society task force panel included expert clinicians and methodologists in pulmonology and intensive care medicine. The task force used the GRADE (Grading of Recommendations, Assessment, Development and Evaluation) methods to summarise evidence and develop clinical recommendations for the use of HFNC alongside conventional oxygen therapy (COT) and noninvasive ventilation (NIV) for the management of adults in acute settings with ARF., Results: The task force developed eight conditional recommendations, suggesting the use of 1) HFNC over COT in hypoxaemic ARF; 2) HFNC over NIV in hypoxaemic ARF; 3) HFNC over COT during breaks from NIV; 4) either HFNC or COT in post-operative patients at low risk of pulmonary complications; 5) either HFNC or NIV in post-operative patients at high risk of pulmonary complications; 6) HFNC over COT in nonsurgical patients at low risk of extubation failure; 7) NIV over HFNC for patients at high risk of extubation failure unless there are relative or absolute contraindications to NIV; and 8) trialling NIV prior to use of HFNC in patients with COPD and hypercapnic ARF., Conclusions: HFNC is a valuable intervention in adults with ARF. These conditional recommendations can assist clinicians in choosing the most appropriate form of noninvasive respiratory support to provide to patients in different acute settings., Competing Interests: Conflict of interest: S. Oczkowski reports support for the current manuscript from librarian support services; support for attending meetings and/or travel from ERS, European Society of Intensive Care Medicine and Society of Critical Care Medicine, outside the submitted work. Conflict of interest: B. Ergan has nothing to disclose. Conflict of interest: L. Bos reports grants from the Dutch Lung Foundation (young investigator grant), the Dutch Lung Foundation and Health Holland (public-private partnership grant), the Dutch Lung Foundation (Dirkje Postma Award), IMI COVID19 initiative and Amsterdam UMC fellowship, outside the submitted work. Conflict of interest: M. Chatwin reports lecture fees from ResMed UK, Breas Medical UK, MPR Italy; and since December 2020 has worked part time for Breas Medical as their global clinical specialist, including CAB membership and support for attending meetings and/or travel. Conflict of interest: M. Ferrer has nothing to disclose. Conflict of interest: C. Gregoretti reports consulting fees from Mindray and Air Liquide; lecture fees from Vivisol, Philips and Air Liquide; support for attending meetings and/or travel from Fisher & Paykel; outside the submitted work. Conflict of interest: L. Heunks reports grants from InflaRx; consulting fees from Liberate Medical, USA; speaker fees from Fisher & Paykel and Maquet; outside the submitted work. Conflict of interest: J-P. Frat reports funding, provision of study materials, personal fees for lectures, travels and accommodations expenses reimbursement from Fisher and Paykel Healthcare; personal fees as a member of a scientific board from SOS Oxygene; grants from French Ministry of health; outside the submitted work. Conflict of interest: F. Longhini reports honoraria for a lecture from Draeger; issued patent for a new device for noninvasive ventilation (European patent number 3320941) from Intersurgical SPA; outside the submitted work. Conflict of interest: S. Nava has nothing to disclose. Conflict of interest: P. Navalesi has nothing to disclose. Conflict of interest: A. Ozsancak Uğurlu has nothing to disclose. Conflict of interest: L. Pisani has nothing to disclose. Conflict of interest: T. Renda has nothing to disclose. Conflict of interest: A.W. Thille reports payments for lectures and support for attending meetings and/or travel from Fisher & Paykel; Fisher & Paykel provided the high-flow nasal oxygen equipment and masks for NIV in several randomised clinical trials coordinated by our center. Conflict of interest: J.C. Winck reports webinar fees from Armstrong Medical, Breas, Philips and Nippon Gases; outside the submitted work. Conflict of interest: W. Windisch reports grants from Philips/Respironics/USA, Löwenstein Medical/Germany, VitalAire/Germany and Vivisol/Germany; speaking fees from Philips/Respironics/USA, Löwenstein Medical/Germany and VitalAire/Germany; outside the submitted work. Conflict of interest: T. Tonia acts as ERS Methodologist. Conflict of interest: J. Boyd is an employee of the European Lung Foundation. Conflict of interest: G. Sotgiu has nothing to disclose. Conflict of interest: R. Scala has nothing to disclose., (Copyright ©The authors 2022. For reproduction rights and permissions contact permissions@ersnet.org.)
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.